Determination of reactogenicity and allergenicity of the immunobiological drug for prevention and treatment of candidiasis

M. V. Rybalkin, N. I. Filimonova, O. P. Strilets, L. S. Strelnikov

Abstract


It is known that the use of drugs, which are capable to stimulate a protective immune response against candidal infection, i.e. immunobiological drugs stimulating protective functions, is a promising direction in the fight against candidiasis. The aim of this work was to study reactogenicity and allergenicity of a new immunobiological drug based on the antigens of C. albicans and C. tropicalis fungi. The study of reactogenicity and allergenicity of the solution of the immunobiological drug for prevention and treatment of candidal infection was carried out in healthy guinea pigs weighing 300-400 g; there were 3 animals in the control and experimental groups each. The experimental animals were dehaired on the sides. To determine reactogenicity the solution of the immunobiological drug in the volume of 0.2 ml was injected intradermally on one side of the body. To determine allergenicity the immunobiological drug in the volume of 0.2 ml was injected intradermally to the experimental animals three times at 14 days intervals, and in 14 days after the last injection the immunobiological drug in the volume of 0.2 ml was injected intradermally to guinea pigs. The animals of the control group were injected with the sterile 0.9% isotonic saline solution. Observations for the presence of local reactions occurrence at the site of injection of the immunobiological drug were performed the first 5 minutes and every 2 hours for 24 hours. As a result of the research conducted it has been found that the immunobiological drug based on the antigens of fungi of C. albicans with the protein concentration of 3 mg/ml and C. tropicalis with the protein concentration of 5 mg/ml in the ratio of 1:1 for prevention and treatment of candidal infection is not reactogenic and allergenic.


Keywords


candidiasis; antigen; vaccine; immunity; therapy

Full Text:

PDF

References


Голубка О.В. // Annals of Mechnikov Institute. – 2011. – №2. – С. 51-59.

Жукова Н.В., Кривошеева И.М. // Кримський терапевт. журн. – 2013. – №2. – С. 99-104.

Краснопольский Ю.М., Борщевская М.И. Фармацевтическая биотехнология. Технология производства иммунобиологических препаратов. – Х.: НТУ «ХПИ», 2009. – 352 c.

Пат. 2352355 РФ, МПК7 A 61 K 39/00, A 61 P 31/00. – 2007139596/13. Заявл.: 25.10.2007. Опубл.: 25.10.2007.

Петров Р.В., Хаитов Р.М. Иммуногены и вакцины нового поколения. – М.: ГЭОТАР-Медицина, 2011. – 608 с.

Семенов Б.Ф., Зверев В.В., Хаитов Р.М. // Журн. микробиол., эпидемиол. и иммунобиол. – 2010. – №2. – С. 105-110.

Carvalho A. // Front. Microbiol. – 2012. – Vol. 3. – P. 1-9.

Cassone A. // Nature Rev. Microbiol. – 2013. – Vol. 11. – P. 884-891.

Rybalkin М.V., Filimonova N.І., Strilets О.P., Strelnikov L.S. // J. of Chemical and Pharmac. Res. – 2014. – Vol. 6, №4. – P. 954-957.

Rybalkin М.V. // Вісник фармації. – 2014. – Т. 78, №2. – С. 78-81.


GOST Style Citations






DOI: https://doi.org/10.24959/88964

Abbreviated key title: Vìsn. farm.

ISSN 2415-8844 (Online), ISSN 1562-7241 (Print)